Congress members ask Gilead CEO to justify Sovaldi's cost; EU recommends several drugs; Docs confess ignorance of biosimilars

@FiercePharma: Yesterday's top-read FiercePharmaManufacturing story: NVS CEO predicts generic industry fallout as quality takes center stage. More | Follow @FiercePharma

@TracyStaton: Contrary to popular belief, side-effect reports on new meds hit a steady pace, study finds. Story | Follow @TracyStaton

@EricPFierce: The FDA says it will boost foreign plant inspections 40%, and cut them by same amount in US. News | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Arkansas court boots $1.2B J&J verdict on technical grounds. Article | Follow @CarlyHFierce

> Gilead Sciences ($GILD) CEO John Martin has been asked by Congressional Democrats to explain how the company arrived at its $84,000 price for its break-through hepatitis C treatment Sovaldi, a drug that is already gaining wide use. Story

> Health Canada has awarded Biogen Idec's ($BIIB) new hemophilia B drug Alprolix its first approval. Release

> European regulators are recommending approval for Boehringer Ingelheim and Eli Lilly's ($LLY) latest diabetes drug, for which the FDA delayed approval earlier this month over manufacturing concerns. Story

> The EU also recommended approval of Takeda Pharmaceutical's treatment for ulcerative colitis and Crohn's disease. Story

Medical Device News

@FierceMedDev: Is there such a thing as a 'gentle' colonoscopy device? Invendo thinks so--and brought in $28M for its new tool. Item | Follow @FierceMedDev

@MarkHFierce: Qiagen hit the Chinese market with its next-gen TB test. Competition looms. More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: MedImmune inks licensing deal with Bioasis for brain delivery platform. Story via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Cochlear scored FDA approval for its innovative hearing aid system. Story | Follow @EmilyWFierce

> Beleaguered Orthofix brings in a new chairman. More

> Yes, U.S. med tech recalls have doubled since 2003--but so has the market. Story

Biotech News

@FierceBiotech: Versartis grabs $126M in an upsized IPO to fund its orphan drug. News | Follow @FierceBiotech

@JohnCFierce: Merck, Endocyte score crucial EMA OK for conditional approval of vintafolide. More | Follow @JohnCFierce

@DamianFierce: EU smiles on Lilly and Boehringer's FDA-rejected diabetes drug. Article | Follow @DamianFierce

@EmilyMFierce: Public-private Japanese partnership invests $15M in neglected diseases. Story | Follow @EmilyMFierce

> Partnerless Aveo is back on the hunt as Biogen returns a cancer drug. Piece

> Novo says Tresiba's down but not out of the blockbuster diabetes race. Read

And Finally... In a new survey 22% of European doctors confess they are not "very familiar" with biosimilars, the biologic knock-offs that payers hope will be quickly accepted to cut healthcare costs. Story

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.